Improving the Identification and Management of Advanced Cutaneous Squamous Cell Carcinoma
September 22, 2022
September 21, 2023
This activity is provided by Practicing Clinicians Exchange.
This activity is supported by an educational grant from Regeneron Pharmaceuticals, Inc. and Sanofi.
- Registered Nurses — 1.00 Nursing contact hours, includes 1.00 hour of pharmacology credit
- Physician Assistants — maximum of 1.00 hours of AAPA Category 1 CME credits
All other healthcare professionals completing this course will be issued a statement of participation.
Oncology NPs, PAs, and nurses.
Although most patients with cutaneous squamous cell carcinoma (cSCC) are diagnosed early in their disease course when curative treatment is possible, those experiencing recurrence and metastasis historically faced a poor prognosis. The advent of immune checkpoint inhibitors (ICIs) has improved survival in patients with advanced cSCC. In this activity, a skin cancer specialist discusses the signs and symptoms of advanced cSCC, guidance and supporting evidence for ICIs, and best practices to identify and manage immune-related adverse events (irAEs).
Upon completion of this activity, participants should be better able to:
- Explain factors to consider in the identification of advanced cSCC
- Integrate ICIs into treatment plans for advanced cSCC based on guideline recommendations and clinical trial data
- Use recommended strategies to identify and manage irAEs in the treatment of advanced cSCC
Nikhil I. Khushalani, MD
Senior Member and Vice Chair
Department of Cutaneous Oncology
H. Lee Moffitt Cancer Center and Research Institute
Kathleen Madden, MSN
Perlmutter Cancer Center
NYU Langone Health
New York, New York
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team
ANCC Credit Designation
NP course advisor: Kathleen Madden, FNP, MSN, AOCNP, APHN, Perlmutter Cancer Center, New York, New York.
Nursing contact hours: 1.00, which includes 1.00 hours of pharmacology credit.
AAPA Credit Designation
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid until September 21, 2023. PAs should only claim credit commensurate with the extent of their participation.
PA course advisor: Jessica Garner, DMSc, PA-C, University of the Pacific, Sacramento, California
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credits for learning and change.
Disclosures of Conflicts of Interest
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
- Nikhil I. Khushalani, MD
- Consultant/Advisor: Array BioPharma, AstraZeneca, Bristol-Myers Squibb, Castle Biosciences, Genzyme, Immunocore, Incyte, Instil Bio, Iovance Biotherapeutics, Jounce Therapeutics, Merck, Nektar, Novartis, Pfizer, Regeneron
- Research Support (paid to institution): Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Huya Bioscience International, Merck, Novartis, Regeneron, Replimune
- Individual publicly traded stocks and stock options: Amarin, Asensus Surgical, Bellicum Pharmaceuticals; other: Bristol-Myers Squibb, Celgene, Nektar, Regeneron, Replimune
- Kathleen Madden, FNP, MSN, AOCNP, APHN
- Consultant/Advisor/Speaker: Novartis
None of the members of the Planning Committee or PCE staff have any relevant financial relationships to disclose, except Kathleen Madden, FNP, MSN, AOCNP, APHN, as noted above.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form.
Certificates will be emailed to the participant.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
Practicing Clinicians requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use..